Inogen, Inc. (NASDAQ:INGN) Given Average Recommendation of “Hold” by Analysts

Inogen, Inc. (NASDAQ:INGN – Get Rating) has been assigned an average recommendation of “Hold” from the eight research firms that are covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $49.80.

Several research analysts recently issued reports on INGN shares. StockNews.com started coverage on Inogen in a research report on Thursday, March 31st. They set a “hold” rating on the stock. TheStreet lowered Inogen from a “c-” rating to a “d” rating in a report on Friday, March 11th.

Shares of NASDAQ INGN opened at $25.24 on Wednesday. Inogen has a 1 year low of $24.92 and a 1 year high of $82.35. The company has a market cap of $576.48 million, a price-to-earnings ratio of -87.03 and a beta of 1.01. The firm has a 50 day simple moving average of $30.98.

Inogen (NASDAQ:INGN – Get Rating) last posted its quarterly earnings data on Thursday, February 24th. The medical technology company reported ($1.01) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.27). The business had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.60 million. Inogen had a negative return on equity of 1.70% and a negative net margin of 1.77%. The business’s revenue was up 3.3% on a year-over-year basis. During the same period last year, the business posted ($0.23) earnings per share. Analysts predict that Inogen will post -1.07 EPS for the current fiscal year.

In other Inogen news, Director Ray Benjamin M. Anderson sold 4,516 shares of the firm’s stock in a transaction dated Thursday, March 3rd. The stock was sold at an average price of $34.68, for a total value of $156,614.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.29% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Macquarie Group Ltd. grew its position in shares of Inogen by 383.9% during the 3rd quarter. Macquarie Group Ltd. now owns 1,079 shares of the medical technology company’s stock valued at $46,000 after purchasing an additional 856 shares in the last quarter. Nisa Investment Advisors LLC grew its position in Inogen by 64.1% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,280 shares of the medical technology company’s stock worth $38,000 after buying an additional 500 shares in the last quarter. Meeder Asset Management Inc. increased its stake in Inogen by 159.8% in the 3rd quarter. Meeder Asset Management Inc. now owns 1,855 shares of the medical technology company’s stock worth $80,000 after acquiring an additional 1,141 shares during the last quarter. Point72 Hong Kong Ltd bought a new position in Inogen in the 3rd quarter worth about $81,000. Finally, Royal Bank of Canada boosted its position in shares of Inogen by 17.8% during the 3rd quarter. Royal Bank of Canada now owns 4,126 shares of the medical technology company’s stock valued at $177,000 after acquiring an additional 622 shares during the last quarter. Institutional investors and hedge funds own 96.01% of the company’s stock.

Inogen Company Profile (Get Rating)

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Featured Articles